Home Newsletters Human Immunology News PD-1 Blockade with Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma: A Multicentre,...

PD-1 Blockade with Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma: A Multicentre, Single-Arm, Phase II Study

By

-

March 15, 2022

Investigators evaluated the activity of pembrolizumab in classic and endemic Kaposi sarcoma with cutaneous extension requiring systemic treatment.

[Lancet Oncology]

Sorry, but the selected Zotpress account can't be found.

Exit mobile version